Axsome Therapeutics (AXSM) Q1 2026 earnings review
Major Approval Offsets a Sequential Stall in Revenue
Axsome's Q1 2026 results present a sharp contrast between long-term potential and near-term execution. On the regulatory front, the FDA's approval of AUVELITY for Alzheimer’s disease (AD) agitation is a massive win, unlocking a completely new, multi-billion dollar market. However, the current financials show momentum is suddenly Reversing. Total revenue dipped sequentially from $196.0M in 25Q4 to $191.2M in 26Q1, breaking a year-long streak of quarterly growth. Simultaneously, the company accelerated its spending ahead of the AD agitation launch, driving SG&A to a record $185M. This toxic combination of flatlining sales and surging expenses caused Net Loss to double sequentially to $64.5M, destroying the steady profitability progress made throughout 2025.
🐂 Bull Case
AUVELITY's approval for AD agitation transforms the drug from a major depressive disorder (MDD) treatment into a broader psychiatric powerhouse. With a June 2026 launch planned, this acts as the primary catalyst for the stock over the next 12-18 months.
Despite the sequential hiccup, total revenue grew 57% year-over-year. The core base of patients taking AUVELITY and SUNOSI remains solid, proving these drugs have established a firm foothold in their respective markets.
🐻 Bear Case
Throughout 2025, Axsome methodically narrowed its net loss from $59.4M to $28.6M. In a single quarter, that progress was erased. The $64.5M net loss in Q1 highlights the immense cost of supporting a 630-person sales force.
Management labeled prescription volume as 'consistent' with Q4, which is a polite way of saying growth has stopped. AUVELITY prescriptions slightly dipped (225k to 223k), and SUNOSI was completely flat (54k to 54k) sequentially.
⚖️ Verdict: ⚪
Neutral. The long-term thesis is significantly derisked with the AUVELITY AD agitation approval, but investors must endure a period of deteriorating margins, stalling sequential volumes, and massive commercial spending before seeing the payoff.
Key Themes
The AUVELITY Alzheimer's Agitation Catalyst
The FDA approved AUVELITY for agitation associated with dementia due to Alzheimer’s disease. This is a game-changer. The launch is slated for June 2026. Axsome has practically doubled its sales force to ~630 representatives to target primary care, psychiatrists, and geriatric specialists. While this guarantees high near-term expenses, it positions the company to tap into a vast, highly underserved Medicare-heavy market where gross-to-net (pricing) dynamics are historically more favorable than in the commercial sector.
SG&A Spending is Accelerating Violently
Operating leverage collapsed in Q1. Selling, General, and Administrative (SG&A) expenses surged to $185.0M—a massive 53% YoY increase and significantly higher than the $169.3M spent last quarter. Management attributes this to the rapid acceleration of pre-launch activities for AD agitation and ongoing direct-to-consumer advertising. Until the new sales reps start generating revenue in Q3/Q4, margins will remain severely compressed.
A Glaring Disconnect in SYMBRAVO Sales
A specific data point contradicts management's narrative of strong execution: SYMBRAVO prescriptions grew an impressive 36% sequentially to 17,000, yet revenue for the drug was completely Stable at exactly $4.1M (identical to 25Q4). This implies that gross-to-net discounting is incredibly severe, or that a vast majority of the new volume is coming from unpaid free samples and aggressive copay cards. Volume without revenue is not sustainable.
Core Franchise Volume is Reversing
Despite a positive spin in the press release, sequential prescription data shows a clear stall. AUVELITY prescriptions slipped from 225,000 in 25Q4 to 223,000 in 26Q1. SUNOSI prescriptions stayed exactly flat at 54,000. When volume stops growing and Q1 insurance resets enforce higher discounts, revenue drops—which is exactly why total product revenue fell by nearly $5M sequentially.
Expanding the Neuroscience Pipeline
Axsome continues to broaden its portfolio beyond depression and sleep. The company quietly acquired AXS-20 (balipodect), a pre-Phase 3 PDE10A inhibitor targeting schizophrenia and Tourette syndrome. Meanwhile, the NDA for AXS-12 (reboxetine) for narcolepsy cataplexy has been submitted, creating yet another near-term commercial shot on goal.
Other KPIs
Accelerating from $44.8M a year ago. The increase primarily reflects a one-time acquisition-related expense (likely tied to the AXS-20 asset) and the ongoing execution of multiple Phase 3 trials across the solriamfetol and AXS-05 lifecycle management programs.
Stable. Down slightly from $322.9M at the end of 2025. Despite the widened net loss, the cash burn was relatively contained in the quarter. Management reiterated its belief that this cash pile is sufficient to fund operations all the way to cash flow positivity, alleviating immediate dilution fears.
Guidance
Stable. Management's long-standing guidance remains unchanged. They believe they will not need to raise additional equity to reach a self-sustaining financial position, though the recent spike in SG&A makes this a tighter runway.
Stable. Topline results for the ENGAGE Phase 3 trial (solriamfetol in Binge Eating Disorder) are expected in the second half of 2026. The SUSTAIN trial for Shift Work Disorder is expected in 2027.
Key Questions
SYMBRAVO Gross-to-Net Pressures
SYMBRAVO prescriptions grew 36% sequentially, yet revenue was completely flat at $4.1M. What is the current gross-to-net discount, and when do you expect pricing dynamics to normalize so volume actually translates into revenue?
SG&A Baseline
With SG&A jumping to $185M in Q1, how much of this was a one-time buildout cost for the Alzheimer's agitation sales force, and what should we consider the new normalized quarterly run-rate going forward?
Stalling Core Volumes
Both AUVELITY and SUNOSI prescription volumes were essentially flat-to-down sequentially in Q1. Was this strictly due to Q1 seasonality and insurance hurdles, or are you seeing a plateau in the current prescriber base before the new 630-rep sales force hits the field?